INT210302

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 2.24
Pain Relevance 0.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (BATF)
Anatomy Link Frequency
plasma 1
SFA 1
limb 1
BATF (Homo sapiens)
Pain Link Frequency Relevance Heat
ischemia 1 98.16 Very High Very High Very High
Central nervous system 1 86.04 High High
agonist 1 54.96 Quite High
Inflammation 32 53.28 Quite High
metalloproteinase 1 52.40 Quite High
cINOD 2 25.56 Quite Low
cytokine 21 5.00 Very Low Very Low Very Low
Dismenorea 18 5.00 Very Low Very Low Very Low
alcohol 9 5.00 Very Low Very Low Very Low
Pain 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Stress 16 99.56 Very High Very High Very High
Cv Unclassified Under Development 1 98.16 Very High Very High Very High
Diabetes Mellitus 100 95.48 Very High Very High Very High
Cardiovascular Disease 72 95.08 Very High Very High Very High
Metabolic Syndrome 53 94.48 High High
Insulin Resistance 18 93.56 High High
Pathologic Constriction 3 92.96 High High
Thrombosis 3 89.24 High High
Peripheral Arterial Disease 55 84.48 Quite High
Coronary Artery Disease 53 80.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The PIER technique is intended as a primary therapy, usually for longer lesions of the SFA and for patients with severe (critical) limb ischemia, and has a 1-year patency rate of 22% and a success rate of 62% [1, 2].
Gene_expression (lesions) of SFA in limb associated with ischemia
1) Confidence 0.55 Published 2007 Journal Cardiovasc Intervent Radiol Section Body Doc Link PMC1914265 Disease Relevance 0.51 Pain Relevance 0.05
The average SFA intake for each person during the 28 day study in the RM and PFS groups was not correlated with plasma palmitic and stearic acid, expressed as a percentage of total plasma fatty acids (Figure 2).


Gene_expression (intake) of SFA in plasma
2) Confidence 0.07 Published 2007 Journal Nutr Metab (Lond) Section Body Doc Link PMC2174488 Disease Relevance 0.11 Pain Relevance 0
Persons in the RM group had a mean intake of SFA that was 32.42 ± 4.62 g/day and the SFA intake of the PFS group was 25.12 ± 2.01 g/day, this difference approached significance (p = 0.137).
Gene_expression (intake) of SFA
3) Confidence 0.07 Published 2007 Journal Nutr Metab (Lond) Section Body Doc Link PMC2174488 Disease Relevance 0.23 Pain Relevance 0
The occurrence of AA and AC polymorphism in patients presenting with SFA were determined as 43.8% and 53.9%, respectively.
Gene_expression (presenting) of SFA in SFA
4) Confidence 0.03 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2828103 Disease Relevance 0.46 Pain Relevance 0
We also found that the incidence of SFA, amongst the TPG, was the most common form of occlusion, results that are in accordance with Meru and colleagues.23
Gene_expression (incidence) of SFA
5) Confidence 0.03 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2828103 Disease Relevance 0.47 Pain Relevance 0.03
Like REM sleep, the temporal pattern of SFA displays a robust circadian rhythm, with the peak of low-frequency SFA (12.25–13.00?
Gene_expression (pattern) of SFA
6) Confidence 0.03 Published 2010 Journal International Journal of Endocrinology Section Body Doc Link PMC2817387 Disease Relevance 0 Pain Relevance 0.07
Proinflammatory Macronutrients
               Proinflammatory macronutrients such as w-6 fatty acids, TFA and SFA as well as refined carbohydrates intake may produce oxidative stress and proinflammatory substances [27] (Figures 1 and 2). 
Gene_expression (produce) of SFA associated with stress
7) Confidence 0.01 Published 2010 Journal Cardiology Research and Practice Section Body Doc Link PMC2910415 Disease Relevance 0.46 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox